Diagnostic and prognostic markers in differentiated thyroid cancer

Current Genomics

Volumn 12, Issue 8, 2011, Pages 597-608

  Gómez Sáez, José M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

AKT; BRAF; Differentiated thyroid cancer; Pi3k; PTEN; RAS; RET

Indexed keywords

B RAF KINASE; CD71 ANTIGEN; GALECTIN 3; HYBRID PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN RET; RAS PROTEIN; TELOMERASE; TRANSCRIPTION FACTOR PAX8;

APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CHERNOBYL ACCIDENT; DIFFERENTIATED THYROID CANCER; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; POINT MUTATION; PROGNOSIS; RADIATION CARCINOGENESIS; SIGNAL TRANSDUCTION; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 82055176824     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920211798120826     Document Type: Article

References (104)

1. Gómez, J.M.; Gómez, N.; Sahún, M.; Rafecas, A.; Villabona, C.; Soler, J. Validity of risk group definition in differentiated thyroid carcinoma. Endocr. Relat. Cancer, 1997, 4, 459-464.
2. Cooper, D.S.; Doherty, G.D.; Haugen, B.R.; Kloos, R.T.; Lee, S.L.; Mandel, S.L.; Mazzaferri, E.L.; McIver, B.; Pacini, F.; Schlumberger, M.; Sherman, S.I.; Steward, D.L.; Tuttle, R.M. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19, 1167-214.
3. Pacini, F.; Schlumberger, M.; Dralle, H.; Elisei, R.; Wiersinga, W. and the European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur. J. Endocrinol., 2006, 154, 787-903.
4. Haugen, B.R.; Woodmansee, W.W.; McDermott, M.T. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors. Clin. Endocrinol. (Oxf), 2002, 56,281-290.
5. Sahin, M.: Gursoy, A.; Tutuncu, N.B.; Guvener, D.N. Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clin. Endocrinol. (Oxf), 2006, 65, 514-518.
6. Letsas, K.P.; Andrikoula, M.; Tsatsoulis, A. Fine needle aspiration biopsy-RT-PCR molecular analysis of thyroid nodules: to useful preoperative diagnostic tool. Minerva. Endocrinol., 2006, 31, 179-182.
7. Fusco, A.; Grieco, M.; Santoro, M.; Berlingieri, M.T.; Pilotti, S.; Pierotti, M.A.; Della Porta, G.; Vecchio, G. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature, 1987, 328, 170-172.
8. Santoro, M.; Dathan, N.A.; Berlingieri, M.T.; Bongarzone, I.; Paulin, C.; Grieco, M.; Pierotti, M.A.; Vecchio, G.; Fusco, A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene, 1994, 9, 509-516.
9. Espinosa, A.; Porchia, L.; Ringel, M. Targeting BRAF in thyroid cancer. Br. J. Cancer, 2007, 96, 16-20.
10. Cohen, Y.; Xing, M.; Mambo, E.; Guo, Z.; Wu G.; Trink, B.; Beller, U.; Westra, W.H.; Ladenson, P.W.; Sidransky, D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst., 2003, 95, 625-627.
11. Kimura, E.T.; Nikiforova, M.N.; Zhu, Z.; Knauf, J.A.; Nikiforov, Y.E.; Fagin, J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res., 2003, 63, 1454-1457.
12. Pierotti, M.A.; Santoro, M.; Jenkins, R.B.; Sozzi, G.; Bongarzone, I.; Grieco, M.; Monzini, N.; Miozzo, M.; Herrmann, M.A.; Fusco, A.; Hay, I.D.; Della Porta, G.; Vecchio, G. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc. Natl. Acad. Sci. USA, 1992, 89, 1616-1620.
13. Pasquali, D.; Santoro, A.; Bufo, P.; Conzo, G.; Deery, W.J.; Renzullo, A.; Accardo, G.; Sacco, V.; Bellastella, A.; Pannone, G. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. Thyroid, 2011, 21, 391-399.
14. Kogan, E.A.; Rozhkova, E.B.; Seredin, V.P.; Paltsev, M.A. Prognostic value of the expression of thyroglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemical studies. Arkh. Patol., 2006, 68, 8-11.
15. Santoro, M.; Carlomagno, F.; Hay, I.D.; Herrmann, M.A.; Grieco, M.; Melillo, R.; Pierotti, M.A.; Bongarzone, I.; Della Porta, G.; Berger, N.; Peix, J.L.; Paulin, C.; Fabien, N.; Vecchio, G.; Jenkins, R.B.; Fusco, A. RET oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest., 1992, 89, 1517-1522.
16. Grieco, M.; Santoro, M.; Berlingieri, M.T.; Melillo, R.M.; Donghi, R.; Bongarzone, I.; Pierotti, M.A.; Della Porta, G.; Fusco, A.; Vecchio, G. PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 1990, 60, 557-563.
17. Bongarzone, I.; Butti, M.G.; Coronelli, S.; Borrello, M.G.; Santoro, M.; Mondellini, P.; Pilotti, S.; Fusco, A.; Della Porta, G.; Pierotti, M.A Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res., 1994, 54, 2979-2985.
18. Ciampi, R.; Giordano, T.J.; Wikenheiser-Brokamp, K.; Koenig, R.J.; Nikiforov, Y.E. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr. Relat. Cancer, 2007, 14, 445-452.
19. Nikiforov, Y.E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol., 2002, 13, 3-16.
20. Rabes, H.M.; Demidchik, E.P.; Sidorow, J.D.; Lengfelder, E.; Beimfohr, C.; Hoelzel, D.; Klugbauer, S. Pattern of radiationinduced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res., 2006, 6, 1093-1103.
21. Zhu, Z.; Ciampi, R.; Nikiforova, M.N.; Gandhi, M.; Nikiforov, Y.E. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab., 2006, 91, 3603-3610.
22. Cunha, N.; Rodrigues, F.; Curadeo, F.; Ilhéu, O.; Cruz C, Naidenov, P.; Rascão, M.J.; Ganho, J.; Gomes, I.; Pereira, H.; Real, O.; Figueiredo, P.; Campos, B.; Valido, F. Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: technique for the diagnosis of metastatic differentiated thyroid cancer. Eur. J. Endocrinol., 2007, 157, 101-107.
23. Tallini, G.; Santoro, M.; Helie, M.; Carlomagno, F.; Salvatore, G.; Chiappetta, G.; Carcangiu, M.L.; Fusco, A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res., 1998, 4, 287-294.
24. Vasko, V.; Ferrand, M.; Di Cristofaro, J.; Carayon, P.; Henry, J.F.; de Micco, C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab., 2003, 88, 2745-2752.
25. Santarpia, L.; Myers, J.N.; Sherman, S.I.; Trimarchi, F.; Clayman, G.L.; El-Naggar, A.K. Genetic alterations in the RAS/RAF/ mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer, 2010, 116, 2974-2983.
26. Garcia-Rostan, G.; Zhao, H.; Camp, R.L.; Pollan, M.; Herrero, A.; Pardo, J.; Wu, R.; Carcangiu, M.L.; Costa, J.; Tallini, G. RAS mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol., 2003, 21, 3226-3235.
27. Nikiforova, M.N.; Lynch, R.A.; Biddinger, P.W.; Alexander, E.K, Dorn, G.W.; Tallini, G.; Kroll, T.G.; Nikiforov, Y.E. RAS point mutation and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab., 2003, 88, 2318-2326.
28. Tallini, G.; Hsueh, A.; Liu, S.; Garcia-Rostan, G.; Speicher, M.R.; Ward, D.C. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab. Invest., 1999, 79, 547-555.
29. Fagin, F.A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J. Endocrinol., 2004, 183, 249-256.
30. Huang, S.M.; Lee, J.C.; Wu, T.J.; Chow, N.H. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J. Surg., 2001, 25, 302-306.
31. Pizzolanti, G.; Russo, L.; Richiusa, P.; Bronte, V.; Nuara, R.B.; Rodolico, V.; Amato, M.C.; Smeraldi, L.; Sisto, P.S.; Nucera, M.; Bommarito, A.; Citarrella, R.; Lo Coco, R.; Cabibi, D.; Lo Coco, A.; Frasca, F.; Gulotta, G.; Latteri, M.A.; Modica, G.; Galluzzo, A.; Giordano, C. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid, 2007, 17, 1109-1115.
32. Chiosea, S.; Nikiforova, M.; Zuo, H.; Ogilvie, J.; Gandhi, M.; Seethala, R.R.; Ohori, N.P.; Nikiforov, Y. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr. Pathol., 2009, 20, 122-126.
33. Santarpia, L.; Sherman, S.I.; Marabotti, A.; Clayman, G.L.; El-Naggar, A.K. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum. Pathol., 2009, 40, 827-833.
34. Namba, H.; Nakashima, M.; Hayashi, T.; Hayashida, N.; Maeda, S.; Rogounovitch, T.I.; Ohtsuru, A.; Saenko, V.A.; Kanematsu, T.; Yamashita, S. Clinical implication of hot spot BRAF mutation,V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab., 2003, 88, 4393-4397.
35. Kumagai, A.; Namba, H.; Akanov, Z.; Saenko, V.A.; Meirmanov, S.; Ohtsuru, A.; Yano, H.; Maeda, S.; Anami, M.; Hayashi, T.; Ito, M.; Sagandikova, S.; Eleubaeva, Z.; Mussinov, D.; Espenbetova, M.; Yamashita, S. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr. J., 2007, 54, 399-405.
36. Xing, M.; Tufano, R.P.; Tufaro A.P.; Basaria, S.; Ewertz, M.; Rosenbaum, E.; Byrne, P.J.; Wang, J.; Sidransky, D.; Ladenson, P.W. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab., 2004, 89, 2867-2872.
37. Domingues, R.; Mendonca, E.; Sobrinho, L.; Bugalho, M.J. Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology, 2005, 16, 27-31.
38. Sapio, M.R.; Guerra, A.; Posca, D, Limone, P.P.; Deandrea, M.; Motta, M.; Troncone, G.; Caleo, A.; Vallefuoco, P.; Rossi, G.; Fenzi, G.; Vitale, M. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr. Relat. Cancer, 2007, 14, 1089-1097.
39. Zatelli, M.C.; Trasforini, G.; Leoni, S.; Frigato, G.; Buratto, M.; Tagliati, F.; Rossi, R.; Cavazzini, L.; Roti, E.; Degli Uberti, E. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine needle aspiration biopsies. Eur. J. Endocrinol., 2009, 161, 467-473.
40. Basolo, F.; Torregrossa, L.; Giannini, R.; Miccoli, M.; Lupi, C.; Sensi, E.; Berti, P.; Elisei, R.; Vitti, P.; Baggiani, A.; Miccoli, P. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab., 2010, 95, 4197-205.
41. Riesco-Eizaguirre, G.; Gutiérrez-Martínez, P.; García-Cabezas, M.A.; Nistal, M.; Santisteban, P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/Itargeting to the membrane. Endocr. Relat. Cancer, 2006, 13, 257-269.
42. Lupi, C.; Giannini, R.; Ugolini, C.; Proietti, A.; Berti, P.; Minuto, M.; Materazzi, G.; Elisei, R.; Santoro, M.; Miccoli, P.; Basolo, F. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 2007, 92, 4085-4090.
43. Nikiforova, M.N.; Nikiforov, Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid, 2009, 19, 1351-1361.
44. Brzezianska, E.; Pastuszak-Lewandoska, D. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cellderived neoplasm. Front. Biosci., 2011, 16, 422-439.
45. Yu, X.M.; Lo, C.Y.; Chan, W.F.; Lam, K.Y.; Leung, P.; Luk, J.M. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin. Cancer Res., 2005, 11, 8063-8069.
46. Soh, E.Y.; Duh, Q.Y.; Sobhi, S.A.; Young, D.M.; Epstein, H.D.; Wong, M.G.; Garcia, Y.K.; Min, Y.D.; Grossman, R.F.; Siperstein, A.E.; Clark, O.H. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J. Clin. Endocrinol. Metab., 1997, 82, 3741-3747.
47. Marshall, C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Genet. Dev., 1994, 4, 82-89.
48. Sherman, S.I. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab., 2009, 94, 1493-1499.
49. Alavi, A.; Hood, J.D.; Frausto, R.; Stupack, D.G.; Cheresh, D.A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science, 2003, 301, 94-96.
50. Carlomagno, F.; Guida, T.; Anaganti, S.; Vecchio, G.; Fusco, A.; Ryan, A.J.; Billaud, M.; Santoro, M. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene, 2004, 23, 6056-6063.
51. Nikiforov, Y. Recent developments in the molecular biology of the thyroid. In: Lloyd RV (ed). Endocrine pathology: differential diagnosis and molecular advances. Humana Press, Totowa, NJ, 2004, pp 191-209.
52. Klein, M.; Vignaud, J.M.; Hennequin, V.; Toussaint, B.; Bresler, L.; Plenat, F.; Leclère, J.; Duprez, A.; Weryha, G.Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab., 2001, 86, 656-658.
53. Zafón, C.; Obiols, G. Vía de señalización dependiente de la proteincinasa de activación mitogénica en el carcinoma papilar de tiroides. De las bases moleculares a la práctica clínica. Endocrinol. Nutr., 2009, 56, 176-186.
54. Cerrato, A.; De Falco, V.; Santoro, M. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J. Mol. Endocrinol, 2009, 43, 143-155.
55. Bauer, A.J.; Terrell, R.; Doniparthi, N.K.; Patel, A.; Tuttle, R.M.; Saji, M.; Ringel, M.D. Francis, G.L. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid, 2002, 12, 953-961.
56. Hu, S.; Liu, D.; Tufano, R.P.; Carson, K.A.; Rosenbaum, E.; Cohen, Y.; Holt, E.H.; Kiseljak-Vassiliades, K.; Rhoden, K.J.; Tolaney S. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer, 2006, 119, 2322-2329.
57. Xing, M.; Usadel, H.; Cohen, Y.; Tokumaru, Y.; Guo, Z.; Westra, W.B.; Tong, B.C.; Tallini, G.; Udelsman, R.; Califano, J.A. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res., 2003, 63, 2316-2321.
58. Liu, D.; Hu, S.; Hou, P.; Jiang, D.; Condouris, S.; Xing, M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res., 2007, 13, 1341-1349.
59. Puxeddu, E.; Durante, C.; Avenia, N.; Filetti, S.; Russo, D. Clinical implication of BRAF mutation in thyroid carcinoma. Trends Endocrinol. Metab., 2008, 19, 138-145.
60. Lui, W-O.; Foukakis, T.; Lidén, J.; Thoppe, S.R.; Dwight, T.; Höög, A. Zedenius, J.; Wallin, G.; Reimers, M.; Larsson, C. Expression profiling reveals a distint transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene. Oncogene, 2005, 24, 1467-1476.
61. Nikiforova, M.N.; Biddinger, P.W.; Caudill, C.M.; Kroll, T.G.; Nikiforov, Y.E. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol., 2002, 26, 1016-1023.
62. Nikiforova, M.N.; Chiosea, S.I.; Nikiforov, Y.E. MicroRNA expression profiles in thyroid tumors. Endocr. Pathol., 2009, 20, 85-91.
63. Nikiforova, M.N.; Tseng, G.C.; Steward, D.; Diorio, D.; Nikiforov, Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab., 2008, 93, 1600-1608.
64. He, H.; Jazdzewski, K.; Li, W.; Liyanarachchi, S.; Nagy, R.; Volinia, S.; Calin, G.A.; Liu, C.G.; Franssila, K.; Suster, S.; Kloos, R.T.; Croce, C.M.; de la Chapelle, A. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA, 2005, 102, 19075-19080.
65. Mazeh, H.; Mizrahi, I.; Halle, D.; Ilyayev, N.; Stojadinovic, A.; Trink, B.; Mitrani-Rosenbaum, S.; Roistacher, M.; Ariel, I.; Eid, A.; Freund, H.R.; Nissan, A. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid, 2011, 21, 111-118.
66. Visone, R.; Russo, L.; Pallante, P.; de Martino, I.; Ferraro, A.; Leone, V.; Borbone, E.; Petrocca, F.; Alder, H.; Croce, C.M.; Fusco, A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer, 2007, 14, 791-798.
67. Nikiforova, M.N.; Gandi, M.; Kelly, L.; Nikiforov, Y.E. MicroRNA dysregulation in human thyroid cells following exposure to ionizing radiation. Thyroid, 2011, 21, 261-266.
68. Mitrani-Rosenbaum, S.; Roistacher, M.; Ariel, I.; Eid, A.; Freund, H.R.; Nissan, A. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid, 2011, 21, 111-118.
69. Gómez Sáez, J.M. Diagnostic usefulness of tumor markers in the thyroid cytological samples extracted by fine-needle aspiration biopsy. Endocr. Metab. Immune Disord. Drug Targets, 2010, 10, 47-56.
70. Moses, W.; Weng, J.; Sansano, I.; Peng, M.; Khanafshar, E.; Ljung, B.M.; Duh, Q.Y.; Clark, O.H.; Kebebew, E. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J. Surg., 2010, 34, 2589-2594.
71. Oberlander, S.; Xie, T.; Chandrachud, U.; Gal, S. Scintillation proximity assay for total p53 protein as an alternative to ELISA. J. Immunol. Methods, 2010, 360, 173-177.
72. Fernández, P.L.; Merino, M.J.; Gómez, M.; Campo, E.; Medina, T.; Castronovo, V. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J. Pathol., 1997, 181, 80-86.
73. Collet, J.F.; Hurbain, I.; Prengel, C.; Utzmann, O.; Scetbon, F.; Beranaudin J.F.; Fajac, A. Galectin-3 immunodetection in follicular thryoid neoplasms: prospective study on fine-needle aspiration samples. Br. J. Cancer, 2005, 93, 1175-1181.
74. Ito, Y.; Yoshida, H.; Tomoda, C.; Miya, A.; Kobayashi, K.; Matsuzuka, F. Galectin-3 expression in follicular tumors: and immunohistochemical study of its uses a marker of follicular carcinoma. Pathology, 2005, 37, 296-298.
75. De Matos, P.; Ferreira, A.P.; de Oliveira Facuri, F.; Saaumpçao, L.V.M.; Metze, K.; Ward, L.S. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaning in the diagnosis of thyroid malignancy. Histopathology, 2005, 47, 391-401.
76. Scognamiglio, T.; Hyjek, E.; Kao, J.; Chen, Y.T. Diagnostic usefulness of HBME1, galectin-3, CK19 and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am. J. Clin. Pathol., 2006, 126, 700-708.
77. Kim, M.J.; Kim, H.J.; Hong, S.J.; Shong, Y.K.; Gong, G. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta. Cytol., 2006, 50, 28-34.
78. Sherman, S.I. Targeted therapy of thyroid cancer. Biochem. Pharmacol., 2010, 80, 592-601.
79. Sherman, E.J.; Fury, M.G.; Tuttle, R.M.; Ghossein, R.; Stambuk, H.; Baum, M.; Lisa, D.; Su, Y.B.; Shaha, A.; Pfister, D.G. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J. Clin Oncol., 2009, 27, 6059.
80. Kondo, T.; Nakazawa, T.; Ma, D.; Niu, D.; Mochizuki, K.; Kawasaki, T.; Nakamura, N.; Yamane, T.; Kobayashi, M.; Katoh, R. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab. Invest., 2009, 89, 791-799.
81. Russo, D.; Damante, G.; Puxeddu, E.; Durante, C.; Filetti, S. Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endocrinol., 2011, 46, R73-R81.
82. Chi, P.; Allis, C.D.; Wang, G.G. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer, 2010, 10, 457-459.
83. Kelly, W.K.; O'Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 3923-3931.
84. Woyach, J.A.; Kloos, R.T.; Ringel, M.D.; Arbogast, D.; Collamore, M.; Zwiebel, J.A.; Grever, M.; Villalona-Calero, M.; Shah, M.H. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab., 2009, 94, 164-170.
85. Imanishi, R.; Ohtsuru, A.; Iwamatsu, M.; Iioka, T.; Namba, H.; Seto, S.; Yano, K.; Yamashita, S. A histone deacetylase inhibitor enhances killing on undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab., 2002, 87, 4821-4824.
86. Yong, J.L.; June-Key, C.; Jae Hoon, S.; Joo Hyun, K.; Jae Min, J.; Dong Soo, L. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid, 2004, 14, 889-895.
87. Smit, J.W.; Schroder-Van der Elst, J.P.; Karperien, M.; Que, I.; Stokkel, M.; van der Heide, D.; Romijn, J.A. Iodide kinetics and experimental (131) I therapy in a xenotransplanted human sodiumiodide symporter-transfected human follicular thyroid carcinoma cell line. J. Clin. Endocrinol. Metab., 2003, 87, 1247-1253.
88. Lee, W.W.; Lee, B.; Kim, S.J.; Jin, J.; Moon, D.H.; Lee, H. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Oncol. Rep., 2003, 10, 845-849.
89. Lin, X.; Fisher, A.H.; Ryu, K-Y.; Cho, J-Y.; Sferra, T.J.; Kloos, R.T.; Mazzaferri, E.L.; Jhiang, S.M. Application of the Cre/Iox system to enhance thyroid targeted expression of sodium/iodide symporter. J. Clin. Endocrinol. Metab., 2004, 89, 2344-2350.
90. Wang, S.L.; Chen, W.T.; Wu, M.T.; Chan, H.M.; Yang, S.F.; Chai, C.Y. Expression of human telomerase to review transcriptase in thyroid follicular neoplasms: an immunohistochemical study. Endocr. Pathol., 2005, 16, 211-218.
91. Lerma, E.; Moor, J.; and the Thyroid Study Group. Telomerase activity in "suspicious" thyroid cancer. Cancer Cytopathol., 2005, 105, 492-497.
92. Magro, G.; Cataldo, I.; Amico, P.; Torrisi, A.; Vecchio, G.M.; Rosalba Parenti, R.; Asioli, S.; Recupero, D.; D'Agata, V.; Mucignat, M.T.; Perris, R. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid, 2011, 21, 267-277.
93. Haberkorn, U.; Altmann, A.; Jiang, S.; Morr, I.; Mahmut, M.; Eisenhut, M. Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur. J. Nucl. Med., 2001, 28, 633-638.
94. Finley, D.J.; Lubitz, C.C.; Wei, C.; Zhu, B.; Fahey, III T.J. Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. Thyroid, 2005, 15, 562-568.
95. Pickett, C.A.; Agoff, S.N.; Widman, T.J.; Bronner, M.P. Altered expression of cyclines and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid, 2005, 15, 461-473.
96. Ito, Y.; Yoshida, H.; Tomoda, C.; Uruno, T.; Takamura, Y.; Miya, A.; Kobayashi, K.; Matsuzuka, F.; Nakamura, Y.; Kakudo, K.; Kuma, K.; Miyauchi, A. Caveolin-1 and 14-3-3 sigma expression in follicular variant of thyroid papillary carcinoma. Pathol. Res. Pract., 2005, 201, 545-549.
97. Ensinger, C.; Kresmer, R.; Prommegger, R.; Spizzo, G.; Schmid, K.W. EpCAM overexpression in thyroid carcinomas: to histopathological study of 121 cases. J. Immunother., 2006, 29, 569-573.
98. Chandan, V.S.; Faquin, W.C.; Wilbur, D.C.; Khurana, K.K. The role of immunolocalization of CD57 and GLUT-1 in cell blocs in fine-needle aspiration diagnosis of papillary thyroid carcinoma. Cancer Cytopathol., 2006, 108, 331-336.
99. Mehrotra, P.; González, M.A.; Johnson, S.J.; Coleman, N.; Wilson, J.A.; Davis, B.R.; Lennard, T.V. Mcm-2 and Ki-67 have limited potential in preoperative diagnosis of thyroid malignancy. Laryngoscope, 2006, 116, 1434-1438.
100. Kebebew, E.; Peng, M.; Reiff, E.; Duh, Q.Y.; Clark, O.H.; McMillan, A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann. Surg., 2005, 242, 353-363.
101. Murugan, A.K.; Xing, M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res., 2011, 71, 4403-4411.
102. Bhaijee, F.; Nikiforov, Y.E. Molecular analysis of thyroid tumors. Endocr. Pathol., 2011, 22, 126-133.
103. Smallridge RC, Marlow, L.A.; Copland, J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer, 2009, 16, 17-44.
104. Towers-Cabala, C.; Bibbo, M.; Panhoist-Santos, A.; Barazi, H.; Krutzsch, H.; Roberts, D.D.; Merino, M.J. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol., 2006, 50, 518-528.